The Aporia
Hynds, J. (2026, October 22). World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist. Daily Mail. https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490
Hynds, Joanna. “World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist.” Daily Mail, 22 Oct. 2026, https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490.
Hynds, Joanna. “World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist.” Daily Mail, October 22, 2026. https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490.
Dated from the outlet's own feed. Check the original for its byline.
A large clinical trial combining Moderna's mRNA cancer vaccine with Merck's immunotherapy drug Keytruda has shown a 42% reduction in the risk of melanoma recurrence or death over two years. The Phase 3 study, involving more than 1,100 patients, also revealed that the combination therapy reduced the likelihood of cancer spreading by 38%. This breakthrough marks a significant step forward for personalized oncology and could pave the way for similar treatments targeting other types of cancers. However, both Moderna and Merck saw their stock prices drop on Thursday after the trial results were leaked online, with Moderna shares falling over 17% and Merck's down about 1.8%. The study was led by Australian scientist Professor Georgina Long from the University of Sydney, highlighting potential global applications for personalized cancer vaccines in treating melanoma and possibly other cancers.